Main Article Content

Parisa Sanawar
Rabia Ghafoor
Nazia Jabeen
Khadija Asadullah
Misbah Qadir
Faiza Inam Siddiqui


Acne Vulgaris, 1% Clindamycin, 5% Dapsone, Topical Therapy


Objective: To evaluate the efficacy of clindamycin phosphate 1% gel versus Once-daily dapsone 5% gel in the treatment of moderate acne vulgaris at Tertiary Care Hospital, Karachi.

Study design: Randomized controlled trial.

Place and duration of study: This study was conducted at Department of Dermatology, Jinnah Postgraduate Medical Centre, Karachi from August 2022 till February 2023.

Material and methods: Data was prospectively collected from patients after taking consent. The sample size for the study was 100 patients, 50 in each group (A-Clindamycin and B- Dapsone) were included. Patients presenting with moderate acne vulgaris in either group were assessed for degree of improvement using Global Acne Grading Scale and patients achieving a score of ≤ 18 after 12 weeks of treatment was labeled as efficacy. Data was analyzed on SPSS Version 24.

Results: The study involved participants aged 20-70 years with Group A (mean age 24.20±5.99) and Group B (mean age 26.221±6.50). In both groups, predominantly there were females, majority in the 20- 49 age range. Efficacy was significantly higher in Group B (82%) compared to Group A (12%). Stratification by gender, and age revealed substantial differences in efficacy, particularly for participants with acne duration ≤ 3 months.

Conclusion: The outcome of this study demonstrates that dapsone 5% gel monotherapy had better efficacious results compared to the clindamycin phosphate 1% gel monotherapy after 12 weeks of treatment, with convenience of once-daily topical application.

Abstract 474 | pdf Downloads 129


1. Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol. 2017 Dec 23;4(2):56-71.
2. Adebamowo C.A., Spiegelman D., Danby F.W., Frazier A.L., Willett W.C., Holmes M.D. High school dietary dairy intake and teenage acne. J Am Acad Dermatol. 2005;52(2):207–14.
3. Agarwal US, Besarwal RK, Bhola K. Oral isotretinoin in different dose regimens for acne vulgaris: A randomized comparative trial. Indian J Dermatol Venereol Leprol. 2011;77(6):688–94.
4. Akman A, Durusoy C, Senturk M, Koc CK, Soyturk D, Alpsoy E. Treatment of acne with intermittent and conventional isotretinoin: a randomized, controlled multicenter study. Arch Dermatol Res. 2007;299(10):467–73.
5. Zhu YI, Stiller MJ. Dapsone and sulfones in dermatology: overview and update. J Am Acad Dermatol. 2001;45(3):420‒434.
6. Ross CM. The treatment of acne vulgaris with dapsone. Br J Dermatol. 1961;73:367‒70.
7. Czemielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(3):5‒12.
8. Nast A, Dreno B, Bettoli V, et al. European evidence-based (s3) guidelines for the treatment of acne-update 2016 short version. J Eur Acad Dermatol Venereol. 2016;30(8):1261‒68.
9. Lynde CW, Andriessen A. Cohort study on the treatment with dapsone 5% gel of mild to moderate inflammatory acne of the face in women. Skinmed. 2014;12(1):15‒21.
10. Taghetti E, Harper JC, Oefelein MG. The efficacy and tolerability of dapsone 5% gel in female Vs males patients with facial and vulgaris, gender as a clinically relevant outcome variable. J Drug Dermatol. 2012;11(12):1417‒21.
11. Brar BK, Kumar S, Sethi N. Comparative evaluation of dapsone 5% gel vs. clindamycin 1% gel in mild to moderate acne vulgaris. Gulf J Dermatol Venereol. 2016;23(1):34-9.
12. Adityan B, Kumari R, Thappa DM. Scoring systems in acne vulgaris. J Dermatol Venereol Leprol 2009;75:323.
13. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet 2012;380:2163-96.
14. Tan AU, Schlosser BJ, Paller AS. A review of diagnosis and treatment of acne in adult female patients. Int J Womens Dermatol 2018;4:56-71.
15. Katsambas A, Towarky AA, Stratigos J. Topical clindamycin phosphate compared with oral tetracycline in the treatment of acne vulgaris. Br J Dermatol 1987;116:387-91.
16. Shalita AR, Smith EB, Bauer E. Topical erythromycin v clindamycin therapy for acne: A multicenter, double-blind comparison. Arch Dermatol 1984;120:351-5.
17. Chu A, Huber FJ, Plott RT. The comparative efficacy of benzoyl peroxide 5%/erythromycin 3% gel and erythromycin 4%/zinc 1.2% solution in the treatment of acne vulgaris. Br J Dermatol 1997;136:235-8.
18. Drucker CR. Update on topical antibiotics in dermatology. Dermatol Ther 2012;25:6‐11.
19. Worret WI, Fluhr JW. Topische Therapie mit Benzoylperoxid, Antibiotika und Azelainsäurebei der Akne (Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid). J Dtsch Dermatol Ges 2006;4:293‐300.
20. Patel M, Bowe WP, Heughebaert C, Shalita AR. The development of antimicrobial resistance due to the antibiotic treatment of acne vulgaris: A review. J Drugs Dermatol 2010;9:655‐64.
21. Guin JD, Reynolds R, Gielerak PL. Penetration of topical clindamycin into comedones. J Am Acad Dermatol 1980;3:153-6.
22. Tan J. Dapsone 5% gel: A new option in topical therapy for acne. Skin Ther Lett 2012;17:1-3.
23. Verma R, Yadav P, Chudhari M, Patel J, Umrigar D. Comparison of efficacy of two topical drug therapy of acne vulgaris–1% clindamycin versus 5% dapsone: A split face comparative study. National Journal of Physiology, Pharmacy and Pharmacology. 2022;12(6):817-22.

Most read articles by the same author(s)